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Abstract
Background: Phospholipase D (PLD) is involved in many signaling pathways. In most systems, the
activity of PLD is primarily regulated by the members of the ADP-Ribosylation Factor (ARF) family
of GTPases, but the mechanism of activation of PLD and ARF by extracellular signals has not been
fully established. Here we tested the hypothesis that ARF-guanine nucleotide exchange factors
(ARF-GEFs) of the cytohesin/ARNO family mediate the activation of ARF and PLD by insulin.
Results: Wild type ARNO transiently transfected in HIRcB cells was translocated to the plasma
membrane in an insulin-dependent manner and promoted the translocation of ARF to the
membranes. ARNO mutants: ∆CC-ARNO and CC-ARNO were partially translocated to the
membranes while ∆PH-ARNO and PH-ARNO could not be translocated to the membranes. Sec7
domain mutants of ARNO did not facilitate the ARF translocation. Overexpression of wild type
ARNO significantly increased insulin-stimulated PLD activity, and mutations in the Sec7 and PH
domains, or deletion of the PH or CC domains inhibited the effects of insulin.
Conclusions: Small ARF-GEFs of the cytohesin/ARNO family mediate the activation of ARF and
PLD by the insulin receptor.
Background
Small GTPases of the ADP-ribosylation factor (ARF) fam-
ily play a major role in membrane trafficking in eukaryotic
cells [1]. ARF activation is facilitated by specific guanine
nucleotide exchange factors (ARF-GEFs). Several ARF-
GEFs have been identified, varying in size, structure and
subcellular distribution [2–6]. Of particular interest in sig-
naling events are the members of the cytohesin/ARNO
family of ARF-GEFs. These proteins have been found to
associate with the plasma membrane under certain condi-
tions, and consist of three well-defined motifs: an N-ter-
minal coiled-coil domain (CC domain), a central domain
with homology to the yeast protein Sec7 (Sec7 domain),
and a C-terminal pleckstrin homology domain (PH
domain) (Fig. 1). The catalytic activity of ARNO for gua-
nine nucleotide exchange is localized in the Sec7 domain
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and appears to be regulated through the interaction of the
PH domain with phosphatidylinositol (PtdIns) (3,4,5)-
P3 [7,8], an intermediate in signaling cascades regulated
by insulin and other agonists [3].
Phospholipase D (PLD) catalyzes the hydrolysis of phos-
phatidylcholine (PC) to produce phosphatidic acid (PA).
It is involved in a variety of signaling pathways and mem-
brane traffic processes [9,10]. Many hormones, neuro-
transmitters, and growth factors, including insulin, have
been shown to induce the activation of PLD [11,12]. Sev-
eral factors are involved in the regulation of cellular PLD
activity, such as Ca2+, protein kinase C, tyrosine kinases,
and G proteins [13–17]. Among these, the members of the
ARF and Rho families of GTPases appear to be the most
potent physiological activators [18–24]. However, the
mechanism of the activation of PLD by ARF and Rho has
not yet been fully established.
This study was designed to investigate the role of ARNO in
the regulation of PLD activity by insulin in HIRcB cells, a
Rat-1 fibroblast cell line that overexpresses human insulin
Schematic structure of ARNO constructs Figure 1
Schematic structure of ARNO constructs. Full length of wild type ARNO and ∆PH-ARNO were subcloned either in 
pCMV-myc or pEGFP-C1. PH-ARNO and ∆CC-ARNO were subcloned in pEGFP-C1. CC-ARNO was subcloned in pEGFP-
N1.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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receptors. The objectives were: 1) to test if insulin induces
the translocation of wild type ARNO to the plasma
membrane in transiently transfected HIRcB cells; 2) to
determine whether ARNO translocation is accompanied
by activation and subcellular translocation of ARF; 3) to
explore if overexpression of wild type ARNO in HIRcB
cells alters insulin-dependent PLD activity; and 4) to
investigate the function of individual domains of ARNO
in insulin-dependent PLD and ARF activation.
Results
Insulin–dependent binding of ARNO to cell membranes
The translocation of ARNO and ARNO mutants to the
membranes was studied in HIRcB cells using a digitonin
permeabilization assay. For these experiments, HIRcB
cells were transiently transfected with myc-tagged wild
type ARNO and the following mutants: ∆PH-ARNO, PH-
ARNO,  ∆CC-ARNO, CC-ARNO, E156K-ARNO and
R280D-ARNO. This assay is based on the formation of
pores in the plasma membrane induced by digitonin to
allow cytosolic proteins to leak out of treated cells upon
centrifugation. Fig. 2 shows that, after digitonin perme-
ablization, a significant fraction of ARNO proteins leaked
out of serum-starved HIRcB cells that transiently overex-
pressed the wild type ARNO and its mutants. Since these
proteins were mostly recovered from the supernatant frac-
tions, suggesting that wild type ARNO and the mutants
tested are predominantly cytosolic in non-stimulated
cells. In contrast, when digitonin permeablization was
performed in the presence of insulin (100 nM), most of
wt-ARNO, E156K-ARNO, and ∆CC-ARNO as well as a
part of CC-ARNO were recovered from the particulate
membrane fraction, suggesting that these ARNO proteins
can be recruited to the membrane by insulin to various
degrees. However, neither R280D-ARNO nor ∆PH-ARNO
was recovered from the particulate fraction after insulin
stimulation, suggesting that the translocation of ARNO to
the membrane requires an intact PH-domain. It should be
noted that, although the CC domain alone binds to the
membranes under stimulation conditions, the degree of
the binding is much less than that of wild type ARNO (Fig.
2). Surprisingly, a construct containing only the PH
domain of ARNO could not be recruited to the mem-
branes by insulin, indicating that the PH domain is essen-
tial but not sufficient for the translocation of ARNO.
ARNO recruits ARF1 to the plasma membrane in an 
insulin-dependent manner
Since ARNO is an activation factor of ARF, we tested the
hypothesis that agonist-dependent ARNO translocation
facilitates the local binding of ARF proteins to the mem-
brane. An initial set of real-time studies was done using
HeLa cells that had been stably transfected with an ARF1-
GFP construct [25]. These cells were transfected with myc-
ARNO, serum-starved overnight, and imaged with a con-
focal microscope equipped with a constant-temperature
microperfusion incubator to maintain the temperature at
37°C. Time-lapse images were collected at 30-second
intervals. A representative experiment was shown in Fig.
3A. Prior to insulin stimulation, ARF1-GFP protein was
mostly cytosolic or bound to the Golgi apparatus,
although a small amount of ARF-GFP was localized on the
surface of the cells. Ten minutes after the insulin stimula-
tion, most of the ARF1-GFP was found on the plasma
membrane. Similar results were obtained with HIRcB cells
co-transfected with ARNO-myc and ARF1-GFP (Fig. 3B). It
should be noted that a significant accumulation of ARF1-
GFP on the plasma membrane was not observed in the
cells that had not been transfected with ARNO (not
shown), or that had been transfected with the inactive
Insulin promotes the translocation of ARNO to cell  membranes Figure 2
Insulin promotes the translocation of ARNO to cell 
membranes. HIRcB cells were transfected with myc-wt-
ARNO, myc-E156K-ARNO, myc-R280D-ARNO, myc-∆PH-
ARNO, EGFP-PH-ARNO, EGFP-∆CC-ARNO, and CC-
ARNO-EGFP. The cells were treated with/without (Control) 
10 µM digitonin (Dig). Where indicated, 100 nM insulin, 1 
mM ATP, and 100 µM GTPγS were present during perme-
ablization reaction. Pellets and supernatants were separated 
by centrifugation and the presence of myc-ARNO and its 
mutants or ARNO-EGFP in each fraction was determined by 
immunoblotting.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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mutant E156K-ARNO (Fig. 3B). Since the endogenous
levels of ARNO in HeLa cells were so low that the protein
could not be detected in Western blots, it is reasonable to
assume that under physiological conditions only a very
small fraction of ARF1 translocates to the plasma mem-
brane in response to extracellular agonists.
ARNO interacts directly with the insulin receptor
Our previous work has shown that the insulin receptor co-
immunoprecipitates with ARF in an agonist-dependent
manner [23]. Furthermore, we have also shown that an
ARF-GEF activity is associated with the insulin receptor
and that this activity is not a function of the receptor itself
[23]. Given that many receptor tyrosine kinases form
complexes with their target proteins, we tested the
hypothesis that ARNO binds the insulin receptor.
Figure 4 shows that insulin receptors that were immuno-
precipitated in the presence of insulin were associated
with an ARF-GEF activity (Fig 4 ● ), and that the ARF-GEF
activity that was co-immunoprecipitated with the insulin
receptor was significantly increased in the cells that had
been transiently transfected with myc-ARNO (Fig. 4 ■ ).
Insulin receptors that were immunoprecipitated in the
absence of insulin did not accelerate the binding of GTPγS
to the recombinant ARF1 as much as those obtained in the
A. Real time image of the translocation of ARF1-GFP to the plasma membrane Figure 3
A. Real time image of the translocation of ARF1-GFP to the plasma membrane. HeLa cells that had been stably 
transfected with ARF1-GFP were transiently transfected with myc-ARNO, serum starved overnight, and treated with 100 nM 
insulin. Images were collected every 30 seconds using a Molecular Dynamics 2001 confocal microscope. The time intervals that 
were indicated on the upper right hand corner of each panel represent the time after the addition of insulin. B. The translo-
cation of ARF1-GFP to the plasma membrane by the effects of insulin requires ARNO. ARF1-GFP/HeLa cells were 
transfected with myc-ARNO, treated, fixed, and stained for myc-epitope as described in the Materials and Methods section. 
Images displaying ARF1-GFP (green) and myc-ARNO (red) were merged us ing Adobe Photoshop software.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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presence of insulin (Fig. 4 ❍ ), indicating that the associa-
tion of ARF-GEF activity with the insulin receptor was
dependent on the presence of insulin.
We then transfected HIRcB cells with myc-tagged ARNO
constructs. Fig. 5 shows that the wild type ARNO co-
immunoprecipitated with the insulin receptor in an insu-
lin-dependent manner. E156K-ARNO was also co-immu-
noprecipitated with the insulin receptor upon insulin
stimulation. However, none of the deletion mutants,
including ∆PH-ARNO, PH-ARNO, ∆CC-ARNO, and CC-
ARNO, as well as a site-directed mutant R280D-ARNO,
was found co-immunoprecipitated with the insulin recep-
tor. These data suggest that ARNO directly interacts with
the insulin receptor and that the interaction requires
intact PH and CC domains, but the catalytic activity of the
Sec7 domain does not alter the interaction.
Effects of the overexpression of ARNO or its mutants on 
insulin-dependent PLD activity
We have shown so far that ARNO mediates the transloca-
tion of ARF proteins to the plasma membrane with insu-
lin stimulation. Since ARF proteins mediate the activation
of PLD by insulin [23], we tested the hypothesis that
ARNO may play a role in the regulation of PLD activitiy
upon insulin stimulation. To prove this point, the PLD
activity of HIRcB cells that had been transiently
transfected with the wild type ARNO, and mutant ARNO
constructs.
The ARF-GDP exchange activity of the coimmunoprecipitates with the insulin receptor Figure 4
The ARF-GDP exchange activity of the coimmunoprecipitates with the insulin receptor. The exchange activity 
was determined as described in Materials and Methods. (❍ ,) Receptors were immunoprecipitated in the absence of insulin 
from cells transfected with empty vector (❍ ) or with myc-ARNO (). (● ,■ ) Receptors were immunoprecipitated in the pres-
ence of insulin from cells transfected with empty vector (● ) or with myc-ARNO (■ ).BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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Fig. 6 shows that the overexpression of the wild type
ARNO significantly increased insulin-induced PLD activ-
ity when compared with that of non-transfected cells. In
contrast, the overexpression of the indicated ARNO
mutants significantly decreased the ability of insulin to
stimulate PLD. We conclude, therefore, that members of
the cytohesin/ARNO family of ARF GEFs play an impor-
tant role in the regulation of PLD activity by insulin.
Discussion
Several studies have demonstrated that ARF proteins may
mediate receptor-dependent activation of PLD. Stimula-
tion of cell surface receptors with agonists, such as insulin,
promotes the translocation of ARF proteins to the cell
membranes and the activation of ARF proteins and the
subsequent activation of PLD [16,18,21,23]. However,
the mechanisms by which ARF proteins are activated by
cell surface receptors remain obscure.
ARF GEFs of the cytohesin/ARNO family have been
shown to be recruited to cell membranes by mechanisms
that are influenced by extracellular agonists [7,26]. These
GEFs have been implicated in the regulation of many cel-
lular processes, ranging from the regulation of cell motil-
ity [27] to cell adhesion [28] and, more recently,
oncogenesis [29]. It has been speculated that PLD activa-
tion may mediate several of the cellular events regulated
by cytohesin/ARNO GEFs [30]. However, a direct proof of
a role for these factors in the regulation of the receptor-
mediated PLD activation is still lacking. To address these
and other related issues, we have studied in detail some of
the mechanistic aspects of this pathway using a fibroblast
cell line that overexpresses human insulin receptors as a
model. This model and other similar ones have been used
in our laboratory and others to examine specific aspects of
insulin receptor function, such as receptor phosphoryla-
tion and traffic [23,31–33] and the regulation of the
MAPK pathway [34].
Our studies showed that insulin promoted the transloca-
tion of myc-tagged ARNO constructs to the plasma
membrane. This result is in agreement with data previ-
ously published by Venkateswarlu et al [7] and Langille et
al [35] who demonstrated the insulin-dependent translo-
cation of ARNO and the related protein GRP-1 to the
plasma membrane, respectively. A detailed analysis of
ARNO deletion and point mutants demonstrated that: 1)
the translocation of ARNO to the membrane is independ-
ent of its ARF-GEF activity; 2) ARNO translocation to the
plasma membrane requires an intact PH domain; 3) the
CC domain of ARNO plays a role in targeting ARNO to
the plasma membrane; 4) neither the PH domain of
Immunoprecipitation of the insulin receptor with ARNO and  its mutants Figure 5
Immunoprecipitation of the insulin receptor with 
ARNO and its mutants. Immunoprecipitated proteins 
were resolved by SDS-PAGE and myc-ARNO, myc-E156K-
ARNO, myc-R280D-ARNO and myc-∆PH-ARNO were 
detected by immunoblotting with a monoclonal anti-myc 
epitope antibody. PH-ARNO-EGFP, ∆CC-ARNO-EGFP, and 
CC-ARNO-EGFP were detected by immunoblotting with a 
polyclonal antibody against EGFP.
Effects of overexpression of the wild type and mutant ARNO  constructs on the activation of phospholipase D by insulin Figure 6
Effects of overexpression of the wild type and mutant 
ARNO constructs on the activation of phospholipase 
D by insulin. HIRcB cells were trans fected with empty vec-
tor, myc-wt-ARNO, myc-E156K-ARNO, myc-R280D-
ARNO, and myc-∆PH ARNO, PH-ARNO-EGFP, ∆CC-
ARNO-EGFP, and CC-ARNO-EGFP. PLD activity was deter-
mined by a transphosphatidylation assay as described in 
Materials and Methods.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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ARNO nor its CC domain alone sufice to target the pro-
tein to the plasma membrane; and 5) the plasma
membrane translocation of ARNO is strongly regulated by
insulin and, perhaps, other extracellular agonists.
The linkage between ARNO translocation to specific sub-
cellular fractions and ARF activation was studied using
myc-tagged ARNO and ARF-GFP constructs in two differ-
ent cell types. Our data showed conclusively that insulin
promoted the co-localization of wild type myc-ARNO and
ARF1-GFP on the surface of HIRcB and HeLa cells. Inter-
estingly, insulin, acting through ARNO, promoted the
translocation of ARF1-GFP to the plasma membrane.
ARF1, like most members of the ARF family, is primarily a
cytosolic protein that exerts its function on specific mem-
branes to which it is recruited by specific activators that
promote the binding of GTP. However, ARF1 seems to act
primarily at the Golgi, promoting the binding of
coatomer proteins to the Golgi membrane [36,37]. Never-
theless, the fact remains that ARF1 is primarily cytosolic,
and that only a small fraction of it is bound to the Golgi
membrane at any time [36]. It is not surprising, therefore,
that some ARF1 may bind to the plasma membrane after
being locally activated by ARNO, which is in turn
recruited to the cell surface by the action of insulin. It
should be remembered that our cells overexpress ARF1-
GFP. Whether ARF1 does in fact work at the plasma mem-
brane under physiological conditions or not remains to
be established. Our data simply establish the fact that a
receptor-dependent mechanism to recruit ARF1 to the
plasma membrane does exist. On the other hand, ARF6 is
normally found associated with the plasma membrane
[36,38], and there is evidence that ARF6 might be the pri-
mary target for ARF-GEFs of the cytohesin/ARNO family
[27]. However, when ARF dominant negative mutants
were tested for their ability to inhibit agonist-dependent
PLD activation, the data showed that ARF1 dominant neg-
ative mutants (T31N-ARF1) were as efficient as ARF6
mutants (T27N-ARF6) [23]. These observations strongly
support the idea that ARF-GEFs of the cytohesin/ARNO
family have full access to the cytosolic ARF proteins.
Therefore, although ARF6 might be the primary interme-
diate for ARNO-regulated PLD activation, other ARF pro-
teins may as well play an important role in the pathway.
The ability of insulin to promote the translocation of
ARNO and ARF to the plasma membrane correlated well
with the ability of insulin to promote the activation of
PLD. Therefore, our data support the hypothesis that the
activation of PLD by insulin is mediated by ARF-GEFs of
the cytohesin/ARNO family by a mechanism that involves
the interaction of the PH and CC domains of these GEFs
with some specific cellular targets. This conclusion is
based on the demonstration that ARNO constructs with
catalytically inactive domain or the mutants with defec-
tive PH and CC domains acted as dominant inhibitors of
insulin-dependent PLD activation. The dominant nega-
tive effects of E156K-ARNO were not unexpected, since
this mutant contains the intact PH and the CC domains
and is therefore likely to compete with endogenous
ARNO. The dominant negative effect of the PH and the
CC domain deletion mutants on PLD activation was of
particular interest. These mutants were at best partially
translocated to the membrane but blocked the ability of
insulin to promote ARF and PLD activation. This result
was somewhat surprising since these deletion mutants
contain an intact Sec7 domain and, therefore, would have
been expected to support ARF and PLD activity. However,
this was not the case, suggesting that all regions of ARNO
play an important role in the regulation of this protein.
Moreover, the failure of the ∆CC mutant to activate ARF
and PLD indicates that other cellular targets that bind to
the CC doma in of ARNO and regulate the subcellular
location or the function of the signaling protein complex
may exist. In fact, some proteins that interact strongly with
the CC domain of members of the ARNO family, such as
CASP and GRASP, have already been identified [39,40].
Consistent with these ideas was the observation that the
overexpression of either the PH or the CC domain alone
was sufficient to block insulin-dependent PLD activation.
Therefore, we propose that cellular targets that recognize
both the PH and CC domains of ARNO are important for
the regulation of the function of this protein by cell sur-
face receptors.
On the other hand, our data also strongly support the
hypothesis that the regulation of ARNO activity by insulin
involves, at least transiently, a direct interaction of the
insulin receptor with ARNO. Consistently, the presence of
an ARNO-like activity and ARNO in the immunoprecipi-
tated materials was confirmed by biochemical experi-
ments. Finally, ARNO constructs lacking either the CC or
the PH domain, or with a defective PH domain, failed to
co-immunoprecipitate with the insulin receptor. These
findings suggest a mechanism of the activation in which
the binding of ARNO to the membrane is regulated by the
insulin receptor at two different levels: 1) ARNO must
interact with the receptor; and 2) ARNO must interact
with the membrane, either via binding to polyphosphoi-
nositides or through the interaction with specific protein
targets. Our data strongly support the idea that both CC
and PH domains play a crucial role in this phenomenon.
Conclusions
This study suggests a general model for the activation of
PLD with insulin stimulation. Insulin, upon binding to its
receptor, promotes the phosphorylation of IRS-1 and the
activation of PI3 kinase. This results in the accumulation
of polyphosphoinositides on the plasma membrane. In
parallel, the insulin-bound receptor promotes the recruit-BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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ment of ARNO (and/or other members of the ARNO fam-
ily, such as GRP-1) to the plasma membrane, either by
direct interaction with their CC and PH domains or by
promoting the interaction of ARNO with other as yet uni-
dentified targets. The binding of ARF-GEFs to the plasma
membrane is stabilized by the interactions of their PH
domain with polyphosphoinositides generated by the
action of PI3 kinase. Once on the membrane, the ARF-
GEFs catalyze the activation of membrane-bound ARF6 or
cytosolic ARF proteins that are then recruited to the mem-
brane where they may activate PLD.
Cell culture
Rat-1 fibroblasts overexpressing the human insulin recep-
tors (HIRcB cells) were cultured in Dulbecco's modified
Eagle's medium (DMEM)/Ham's F-12, supplemented
with 10% fetal bovine serum, antibiotics, and 100 nM
methotrexate, as previously described [20]. Cells were
subcultured, transfected as indicated in the figure legends,
and serum starved for overnight (approximately 20 hrs)
prior to insulin stimulation.
HeLa cells were cultured in DMEM supplemented with
10% fetal bovine serum and antibiotics. HeLa-ARF1-GFP
stable transfectants were obtained by using G418 as a
selection agent as described elsewhere [25]. Clonal popu-
lations were obtained and used in the assays described
here.
Transient Transfection
Subconfluent (70–90%) HIRcB cells were transfected with
LipofectAMINE (Invitrogen) for biochemical analyses or
Superfect (QIAGEN) for imaging analyses. Transfection
was performed according to the manufacturer's instruc-
tions. Transfection efficiencies were 70–90% for Lipo-
fectAMINE and 40–50% for Superfect transfection reagent
as previously described [41].
Generation of fusion proteins
It has been reported that the members of the cytohesin/
ARNO family of ARF-GEFs each exist in two isoforms in
terms of existence of extra G (glycine) in PH domain [42].
In this study, we used the isoform of ARNO with GGG
(tri-glycine), which has similar binding affinities for both
PI-(3,4,5)-P3 and PI-(4,5)-P3. The following myc-tagged
ARNO constructs were generated: wt-ARNO, ∆PH-ARNO,
PH-ARNO,  ∆CC-ARNO, E156K-ARNO, and R250D-
ARNO. wt-ARNO, ∆PH-ARNO (amino acids 1 to 269),
PH-ARNO (amino acids 262–399), and ∆CC-ARNO
(amino acids 51–399) (Fig. 1) were amplified by PCR and
subcloned in the multiple cloning site of the vector
pEGFP-C1 (CLONTECH) and fused to green fluorescent
protein (GFP) as described by Venkateswarlu and cowork-
ers [7]. The CC domain of ARNO (amino acids 1 to 55)
(Fig. 1) was PCR out of wt-ARNO and subcloned into
pEGFP-N1 using BglII and EcoRI restriction sites. E156K-
ARNO (inactive Sec7 domain) was generated by site-
directed mutagenesis as described by Frank and coworkers
[43]. R280D-ARNO was designed on the basis of that a
mutation on an analogous arginine impairs the binding
of cytohesin-1 to polyphosphoinositides [26]. The
sequences of the constructs were verified by direct
sequencing and the expression of appropriate fusion
proteins was examined by Western blotting. The level of
expression of all constructs was found to be comparable.
Immunoprecipitation assay
Transfected and serum-starved HIRcB cells were washed
with ice-cold PBS, scraped, and collected by centrifuga-
tion. The cell pellets were solubilized on ice for 1 hr in a
solution of 50 mM Hepes, pH 7.45, containing 100 mM
NaCl, 1.5% sodium cholate, 1 mM EDTA, 1 mM EGTA, 5
ug/ml leupeptin, 1 mM PMSF, and 1 mg/ml soybean
trypsin inhibitor. Insoluble materials were removed by
centrifugation. The cell lysate was immunoprecipitated
with anti-mouse IgG agarose that had been equilibrated
with a monoclonal antibody 83.7 (which recognizes the α
subunit of the human insulin receptor). Immunoprecipi-
tation was carried out overnight (approximately 20 hrs) at
4°C. The immunoprecipitates were washed with lysis
buffer, resuspended in SDS-PAGE sample buffer, and sub-
jected to Western blotting analysis.
Immunoblotting
Proteins were separated by SDS-PAGE, transferred to a
nitrocellulose membrane, and blocked with 5% non-fat
milk in PBS containing 0.1% Tween at room temperature
for 2 hrs. The membrane was then cut in half horizontally.
The upper part was used to detect the β subunit of the
insulin receptor with a monoclonal antibody, CT-1, that
recognizes the carboxyl terminus of the β subunit of the
human insulin receptor. The lower part was used to detect
ARNO proteins with a monoclonal antibody anti-myc or
a polyclonal antibody anti-GFP.
PLD activity assay
Serum-starved HIRcB cells were labeled overnight with
3H-palmitate (5 µCi/ml) in serum-free medium. The cells
were stimulated with insulin (100 nM) in the presence of
0.5–1% ethanol for 20 min. The reaction was stopped by
addition of chloroform: methanol (1:1). The lipid phase
was extracted and developed by thin layer chromatogra-
phy (TLC) on silica gel 60 plates using ethyl acetate:
trimethylpentane: acetic acid (9: 5: 2) as a solvent. The
position of major phospholipids was determined using
true standards (Avanti Biochemicals) and autoradiogra-
phy. The TLC plates were scraped and the total amount of
radioactivity associated with each lipid species was deter-
mined by liquid scintillation counting. The data were
expressed as the number of counts associated with theBMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/13
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phosphatidylethanol (PtdEtOH) spot normalized by the
total number of counts of lipid.
Digitonin treatment
Serum-starved HIRcB cells were collected, resuspended in
PBS, and treated with 10 µM digitonin in the presence or
absence of insulin (100 nM), ATP (1 mM), and GTPγS
(100 µM) at 37°C for 15 min. To release intracellular pro-
teins, the digitonin-treated cells were centrifuged in a
microcentrifuge for 20 min. The supernatants and the cell
pellets were collected separately, and subjected to SDS-
PAGE. ARNO proteins were detected by immunoblotting
as described above.
In vitro ARF activation assay
ARF activation was determined by the binding of GTPγS to
the purified, myristoylated recombinant human ARF1
(mhARF1), as described by Shome and coworkers [23].
The insulin receptor was immunoprecipitated in the pres-
ence or absence of 100 nM insulin as described above.
Four to 8 µg mhARF1 and the immunoprecipitated insu-
lin receptors were incubated with 100 nM GTPγ[35S] (1
µCi) in 20 mM Hepes buffer containing 2 mM MgCl2/
0.1% Na-cholate / 1 mM ATP. At the indicated time
points, the reaction was quenched by addition of 100 µM
ice-cold, unlabeled GTPγS and the protein-bound nucle-
otide was determined by filtration through nitrocellulose
filters as described [23].
Confocal microscopy
HIRcB cells were plated on poly-L-lysine coated glass cov-
erslips and transfected with the constructs as indicated
above. Cells were serum starved overnight and stimulated
with 100 nM insulin. Live cells were imaged in a LSM5
Zeiss laser scanning confocal microscope equipped with a
63X oil immersion objective.
For ARF and ARNO colocalization experiments, HIRcB
cells were plated on poly-L-lysine coated coverslips as
described above and co-transfected with myc-ARNO and
ARF-GFP constructs using Superfect transfection reagent
according to the manufacturer's instructions. Following
insulin stimulation, the cells were fixed with 4% fresh
paraformaldehyde in PBS at 4°C for 30 min, and perme-
abilized in 0.1% Triton X-100 at room temperature for 2
min. After permeabilization, the cells were blocked with
3% bovine serum albumin in PBS at room temperature
for 30 min, and immunostained with a monoclonal anti-
body 9E10 (Upstate Biotechnology) that recognizes the
myc epitope. After extensively washing, the cells were
incubated with a Cy5-conjugated donkey anti-mouse sec-
ondary antibody (Jackson Immunoresearch) and imaged
using a Zeiss laser scanning confocal microscope with fil-
ters appropriate for the detection of GFP and Cy5.
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